南方医科大学学报2025，Vol.45Issue(4)：760-764,5.DOI:10.12122/j.issn.1673-4254.2025.04.11
地舒单抗治疗的原发性骨质疏松症患者血钙及骨代谢标志物的动态变化
Changes in circulating levels of calcium and bone metabolism biochemical markers in patients receiving denosumab treatment
摘要
Abstract
Objective To investigate the changes in blood levels of calcium and bone metabolism biochemical markers in patients with primary osteoporosis receiving treatment with denosumab.Methods Seventy-three patients with primary osteoporosis treated in our Department between December,2021 and December 2023 were enrolled.All the patients were treated with calcium supplements,vitamin D and calcitriol in addition to regular denosumab treatment every 6 months.Blood calcium,parathyroid hormone(PTH),osteocalcin(OC),type I procollagen amino-terminal propeptide(PINP),and type I collagen carboxy-terminal telopeptide β special sequence(β-CTX)data before and at 3,6,9,and 12 months after the first treatment were collected from each patient.Results Three months after the first denosumab treatment,the bone turnover markers(BTMs)OC,PINP,and β-CTX were significantly decreased compared to their baseline levels by 39.5%(P<0.001),56.2%(P<0.001),and 81.8%(P<0.001),respectively.At 6,9,and 12 months of treatment,OC,PINP,and β-CTX remained significantly lower than their baseline levels(P<0.001).Blood calcium level was decreased(P<0.05)and PTH level increased(P<0.05)significantly in these patients at months of denosumab treatment,but their levels were comparable to the baseline levels at 6,9,and 12 months of the treatment(P>0.05).Conclusion Denosumab can suppress BTMs and has a good therapeutic effect in patients with primary osteoporosis,but reduction of blood calcium and elevation of PTH levels can occur during the first 3 months in spite of calcium supplementation.Blood calcium and PTH levels can recover the baseline levels as the treatment extended,suggesting the importance of monitoring blood calcium and PTH levels during denosumab treatment.关键词
地舒单抗/骨质疏松症/血钙/甲状旁腺素/骨转换指标Key words
denosumab/osteoporosis/circulating calcium/parathyroid hormone/bone turnover markers引用本文复制引用
陈远程,吴文,许翎,邓海鸥,王瑞雪,黄倩雯,禤立平,陈雪莹,智喜梅..地舒单抗治疗的原发性骨质疏松症患者血钙及骨代谢标志物的动态变化[J].南方医科大学学报,2025,45(4):760-764,5.基金项目
广东省基础与应用基础研究基金区域联合基金青年项目(2023A1515111069) （2023A1515111069）
中国脆性骨折高风险患者管理与骨治疗不良反应监测项目(骨力计划) （骨力计划）
